SCHEMBL6080339

SCHEMBL6080339

COC(=O)c1nc2c(C#N)cccc2c(O)c1Br

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.36
ADORA1 P30542 1/20 0.36
ALDH1A1 P00352 5/20 0.36
KDM4E B2RXH2 4/20 0.35
STAT3 P40763 1/20 0.35
HIF1A Q16665 1/20 0.35
GAA P10253 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
TSHR P16473 1/20 0.35
MAPT P10636 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
HPGD P15428 1/20 0.34
CRHBP P24387 1/20 0.34
CRHR2 Q13324 1/20 0.34
ERCC1 P07992 1/20 0.34
FEN1 P39748 1/20 0.34
ERCC4 Q92889 1/20 0.34
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6080873 0.84 ADORA2A (0.36) ADORA2AADORA1KDM4ECA1CA2
SCHEMBL6079815 0.83 CA12 (0.45) ALDH1A1KDM4ESTAT3HIF1AGAA
SCHEMBL6080471 0.81 ALDH1A1 (0.40) ADORA2AALDH1A1KDM4ESTAT3HIF1A
SCHEMBL6080451 0.78 ALDH1A1 (0.43) ADORA2AADORA1ALDH1A1KDM4EHIF1A
SCHEMBL31726661 0.76 MAPT (0.41) ADORA2AADORA1ALDH1A1KDM4EGAA
SCHEMBL6080818 0.76 NPSR1 (0.39) ALDH1A1KDM4ESTAT3HIF1AGAA
SCHEMBL6079703 0.74 ALDH1A1 (0.40) ALDH1A1KDM4EGAASMN1; SMN2MAPT
SCHEMBL31726174 0.74 ALDH1A1 (0.40) ALDH1A1KDM4EGAASMN1; SMN2MAPT
SCHEMBL6079707 0.74 KDM4E (0.48) ALDH1A1KDM4ESTAT3HIF1ASMN1; SMN2
SCHEMBL6080122 0.74 SLC22A12 (0.37) ADORA2AADORA1ALDH1A1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US claimed
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NQO1, NQO2, RECQL ADORA2A 1442/4885ADORA1 1161/4885ALDH1A1 2726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.